On July 25, 2025, Ikena Oncology, Inc. merged with Inmagene Biopharmaceuticals and changed its name to ImageneBio, Inc., with shareholders receiving new common shares based on a set exchange ratio. Following the merger, Inmagene shareholders own about 43.5% of the new company, which focuses on therapies for immunological diseases.